About us

Founded in 2018 and headquartered in Cambridge, MA, our team of experts in molecular biology and drug discovery is developing a technology that reprograms the autophagy pathway to degrade disease targets.

  • Our mission

    To deliver novel therapeutics through a deeper understanding and engineering of autophagy.

  • Our vision

    To aspire to restore health by eliminating cellular damage.

Our team

Meet the Casmaniacs

Our team is given the freedom to explore novel approaches that we believe will lead to richer discovery.

Meet our team

Our story

Casma is a new kind of degradation company focused on the autophagy pathway. Developed through our extensive expertise in cell biology and unique drug discovery capabilities, our highly differentiated discovery engine identifies important autophagy disease targets beyond singular proteins. Our PHLYT™ platform allows us to permanently eliminate these disease-causing elements inside cells.

The science: autophagy

Learn what autophagy is, how it works, and why it matters.

Explore the science

Platform & pipeline

See how cool PHLYT™ is!

See our progress